GFAP and Alzheimer disease: Moreover, GSPM treatment, both at low and high doses, significantly reduced the proportion of AD plaque-associated microglia (Iba1 expression) and astrocytes (GFAP activation) (Figure 1F), indicating alleviated neurological inflammation.